Skip to main content
menu

Center for Health + Technology [CHeT]

URMC / Center for Health + Technology / Our Expertise / CHeT Outcomes / LC-HI: The Lung Cancer Health Index

 

LC-HI: The Lung Cancer Health Index

  • Type of Clinical Outcome Assessment (COA): Patient-reported outcome measure (PRO)
  • Administration Mode: Self-administered
  • Therapeutic Area: Lung cancer
  • Approximate Completion Time: <10 minutes
  • Required Supervision: None
  • Recall Period: Immediate point in time

Instrument Variations

  • The Lung Cancer Health Index Short Form (LC-HI-SF)
    • LC-HI Short From Completion Time: Under 1 minute

Symptom Subscales

  • Number of Independently Validated Symptom Subscales: 10

Fatigue; Physical Function; Emotional Health; Sleep & Daytime Sleepiness; Activity Participation; Breathing; Gastrointestinal Health; Cognition; Social Satisfaction; Pain

Instrument Attributes

  • The LC-HI is a patient-reported outcome (PRO) measure designed to assess symptoms and health-related quality-of-life from the perspective of patients with lung cancer.
  • Designed and validated to fully satisfy regulatory and published FDA guidance for use in drug-labeling claims and measuring changes in how a patient feels and functions.
  • The LC-HI is a fully valid, reliable, responsive, and disease-specific instrument capable of measuring changes in patient-reported health in patients with lung cancer.
  • The instrument was developed using extensive patient input, including an analysis of 653 patient quotes and a large cross-sectional study involving 139 patients.
  • The LC-HI is highly relevant to patients, has low patient burden, correlates with markers of disease severity, and demonstrates low floor and no ceiling effects.
  • The LC-HI and its subscales demonstrated a high internal consistency (Cronbach α = 0.97 for the full instrument).
  • English

Additional translations available upon request.

  • Varma A, Weinstein J, Seabury J, Rosero S, Zizzi C, Dilek N, Heatwole J, Baumgart M, Mulford D, Maggiore R, Conrow L, King JC, Wiens J, Heatwole C. Patient-reported impact of symptoms in lung cancer (PRISM-LC). Transl Lung Cancer Res. 2023 Jul 31;12(7):1391-1413. doi: 10.21037/tlcr-22-831. Epub 2023 Jul 11. PMID: 37577309; PMCID: PMC10413040.
  • “Development and Validation of the Lung Cancer-Health Index (LC-HI), A Clinically-Relevant, Disease-Specific Patient-Reported Outcome Measure.” A. Varma, S. Rosero, J. Weinstein, C. Engebrecht, C. Zizzi, N. Dilek, J. Heatwole, M. Baumgart, D. Mulford, R. Maggiore, L. Conrow, J. King, J. Wiens, C. Heatwole. American Association for Cancer Research (AACR) Annual Meeting. Orlando, FL. 4/14/23.

Instrument Scoring

All subscales are scored on a scale of 0 to 100 with 0 representing no disease burden and 100 representing the maximum level of disease burden. Symptom questions within each subscale are weighted based on participant-reported prevalence and average impact as identified through the cross-sectional study. Subscale scores are also weighted to generate a total LC-HI score (0-100) representing overall disease burden.

Inquire about Licensing   View All Instruments